Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major aim of patient immune monitoring is the identification of biomarkers that predict clinical outcome. We studied circulating myeloid-derived suppressor cells (MDSC) in ipilimumab-treated patients to detect alterations in the myeloid cell compartment and possible correlations with clinical outcome. Lin(-) CD14(+) HLA-DR(-) monocytic MDSC were enriched in peripheral blood of melanoma patients compared to healthy donors (HD). Tumor resection did not significantly alter MDSC frequencies. During ipilimumab treatment, MDSC frequencies did not change significantly compared to baseline levels. We observed high inter-patient differences. MDSC frequencies in ipilimumab-treated patients were independent of baseline serum lactate dehydrogenase levels but tended to increase in patients with severe metastatic disease (M1c) compared to patients with metastases in skin or lymph nodes only (M1a), who had frequencies comparable to HD. Interestingly, clinical responders to ipilimumab therapy showed significantly less lin(-) CD14(+) HLA-DR(-) cells as compared to non-responders. The data suggest that the frequency of monocytic MDSC may be used as predictive marker of response, as low frequencies identify patients more likely benefitting from ipilimumab treatment. Prospective clinical trials assessing MDSC frequencies as potential biomarkers are warranted to validate these observations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“both a low baseline frequency of MDSCs and a low frequency of MDSCs in the blood of patients with melanoma following ipilimumab treatment were associated with favorable therapy outcome (134, 169-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“patients with cancer who have high levels of circulating MDSCs have been found to respond poorly to checkpoint blockade”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Meyer et al., 2014
Experimental — accuracy not yet measuredIn the citing paper
“lower numbers of MDSCs in melanoma patients were associated with a better response to Ipilimumab (CTLA-4 antibody) (Meyer et al., 2014).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Meyer et al., 2014
In the citing paper
“numerous studies of patients with cancer have indeed found that these myeloid cell subsets, whether in the tumor or in peripheral tissues, were negatively correlated with effective ICI therapy (134, 161, 168-171).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 5×
“However, autoimmune responses are also promoted, as 10–15 % of patients develop severe grade 3–4 immune-related adverse events [8].”
BackgroundInfluentialThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“Recently, the fully humanized anti-CTLA-4 antibody ipilimumab was reported to increase overall survival of stage III/IV metastatic melanoma patients [8, 9].”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“Different malignancies favor the accumulation of different MDSC phenotypes in patients [29].”
BackgroundWolchok, J. D., Hoos, A., O'Day, S., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,222
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“About 50 % of melanomas express BRAF-activating mutations [4], which are V600E and V600K substitutions in 95 % of cases [5].”
Background
Cited by
Items 501–600 of 617
Shen, A., Arbesman, M., Lodha, R., Rayman, P. A., Gastman, B., Ko, J. S., Truong, T., Diaz-Montero, C. M., Ni, Y., Funchain, P., et al. (2025) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.12.016 · Cited by 2
Immune-checkpoint inhibition for tumor prevention in a preclinical Lynch syndrome model
Wolff, A., Maennicke, J., Hühns, M., Krone, P., Oehmcke-Hecht, S., Redwanz, C., Bergmann‐Ewert, W., Junghanss, C., & Maletzki, C. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102472 · Cited by 2
Wang, Y., Li, S.-Y., Chen, S.-Q., Wang, L., & Han, Z. (2022) · Current Medical Science · doi:10.1007/s11596-022-2623-3 · Cited by 2
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors
Bořilová, S., Grell, P., Bílek, O., & Kišš, I. (2020) · Onkologie · doi:10.36290/xon.2020.075 · Cited by 1
Yu, S., Shu, W., Zhang, J., Cheng, S., Shen, X., Chen, G., Zhang, T., Dong, K., Zhang, J., Laudański, P., et al. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s583327 · Cited by 1
Wierz, M. (2020) · theses.fr (ABES) · doi:10.70675/80454a47z3b6bz4b8bza0c3z684d69f087b3 · Cited by 1
Xu, J., Ni, C., Qin, L., Wang, P., & Xu, J. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04330-8 · Cited by 1
Front line of cancer immunotherapy development
Kitano, S. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.2645 · Cited by 1
Targeted delivery and reprogramming of myeloid-derived suppressor cells (MDSCs) in cancer
Katoh, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00015-4 · Cited by 1
Arleo, A., Montagner, A., Giovannini, C., Suzzi, F., Piscaglia, F., & Gramantieri, L. (2024) · Biomolecules · doi:10.3390/biom14121496 · Cited by 1
Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy
Maniyar, R. R., Chakraborty, S., Jarboe, T., Suriano, R., Wallack, M. K., Geliebter, J., & Tiwari, R. K. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-83282-7_6 · Cited by 1
Tissue Infiltrating Immune Cells and Endometrial Cancer Prognosis
Drakes, M. L., Mehrotra, S., Potkul, R. K., Czerlanis, C. M., & Stiff, P. J. (2021) · Clinical Oncology and Research · doi:10.31487/j.cor.2021.04.01 · Cited by 1
Immunotherapy for Renal Cell Cancer (RCC)
Kitano, S., Ito, A., & Kim, Y. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_12 · Cited by 1
Developing predictive biomarkers for endometrial cancer immunotherapy with mass cytometry (CyTOF)
Fuh, K. C., Huang, Y.-W., Lomonosova, E. E., & Fantl, W. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822213-3.00001-2 · Cited by 1
Slusny, B., Zimmer, V., Nasiri, E., Lutz, V., Huber, M., Buchholz, M., Gress, T. M., Roth, K. S., & Bauer, C. A. (2024) · Cancers · doi:10.3390/cancers17010051 · Cited by 1
Wiktorin, H. G., Ekström-Rydén, V., Ek, I., Eriksson, E., Lövgren, T., Nordström, C. B., Sandin, L. C., Patel, M. R., Hamid, O., Ullenhag, G. J., et al. (2026) · Biomarker Research · doi:10.1186/s40364-026-00917-z · Cited by 1
Raizada, D., & Gomes, A. P. (2026) · Genes & Development · doi:10.1101/gad.353830.126 · Cited by 1
Douguet, L. (2015) · theses.fr (ABES) · doi:10.70675/545bac4bz3a58z4433zae13z7dcd3b62df8a · Cited by 1
Patient-derived three-dimensional lung tumor models to evaluate response to therapy
Goliwas, K. F., Desai, A. P., Hough, K. P., Sivan, S., Single, S. L., Puritipati, N., Tom, A. G., Alhushki, S., Deshmukh, S. S., Berry, J. L., et al. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01559-y · Cited by 1
XBP1 signaling from tumor metabolic stress to myeloid driven immunotherapy resistance (Review)
Chen, Z., Wu, J., Liu, W., Tan, J., Peng, X., Zhang, Y., & Liang, G. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5951 · Cited by 1
Zhang, Y., & Wang, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.22.753629 · Cited by 1
Investigating the Effects of Chronic Low-Grade Inflammation on Cancer Immunotherapy
Evans, M. (2018) · Otago University Research Archive (University of Otago) · Cited by 1
Gielen, P. R. (2016) · Radboud Repository (Radboud University) · Cited by 1
Immunity and Beyond: Emerging Roles of Monocytes and Macrophages in Cancer
Tomás, A., & Pojo, M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-12166-0_7
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2019) · Springer eBooks · doi:10.1007/978-3-319-46029-1_39-1
Research status and prospect of immune checkpoint inhibitors for melanoma
Liang, Y., Liu, T., & Wu, Y. (2022) · International Symposium on Artificial Intelligence for Medicine Sciences (ISAIMS) · doi:10.1145/3570773.3570784
Münz, C., & Chijioke, O. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735084294.793557461
Weppler, A. M., Lau, P. K. H., & McArthur, G. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_39
Emerging Biomarkers of Response to Immunotherapy: Host Characteristics in Breast Cancer
Mathesh, V., & Reddy, S. M. (2025) · Cancer immunotherapy · doi:10.1007/13905_2024_44
Highlights of the season 2016–2017 by the Spanish Melanoma Group (GEM)
On behalf of the Spanish Melanoma Group (GEM), Soria, A., Manzano, J. L., Berrocal, A., Espinosa, E., Márquez‐Rodas, I., González‐Cao, M., & Martín‐Algarra, S. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.37
Recent advance in immune checkpoint inhibitors-based therapy of advanced hepatocellular carcinoma
Mo, J., Guo, Z., Zhang, S., Huang, G., & Cai, T. (2024) · Archives of Medical Science · doi:10.5114/aoms/188722
Liu, Y., Sun, Y., Wang, P., Li, S., Yiwei, D., Zhou, M., 石必枝, Jiang, H., Sun, R., & Li, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26581793
Hegde, A. M., Jayaprakash, P., Couillault, C., Piha-Paul, S. A., Karp, D. D., Rodon, J. A., Pant, S., Fu, S., Dumbrava, E. E. I., Yap, T. A., et al. (2023) · doi:10.1158/1078-0432.c.6530310.v1
Gandhi, S., Pandey, M. R., Attwood, K. M., Ji, W., Witkiewicz, A. K., Knudsen, E. S., Allen, C. L., Tario, J. D., Wallace, P. K., Cedeno, C. D., et al. (2023) · doi:10.1158/1078-0432.c.6530279
Martens, A., Wistuba‐Hamprecht, K., Yuan, J. D., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., et al. (2023) · doi:10.1158/1078-0432.22467407
Controversies in Neoplastic Myeloplasia
Talmadge, J. E. (2016) · SpringerBriefs in immunology · doi:10.1007/978-3-319-26821-7_1
REOVIRUS-DRIVEN MYELOID CELLS IN ONCOLYTIC VIRUS THERAPY AND INFECTION
Clements, D. R. (2018) · DalSpace (Dalhousie University)
Champiat, S. (2019) · theses.fr (ABES) · doi:10.70675/e358773dz1898z4feezbb3bzbdee7c7f20a6
Modulation of Myeloid-Derived Suppressor Cells Amplification by Tumor Microenvironment
张, 瑞. (2021) · Advances in Clinical Medicine · doi:10.12677/acm.2021.1111741
Checkpoint Blockade in Hematologic Malignancies
Charalambous, A., & Schwarzbich, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_178-1
Douglass, S. M., Fane, M. E., Sanseviero, E., Ecker, B. L., Kugel, C. H., Behera, R., Kumar, V., Tcyganov, E. N., Yin, X., Liu, Q., et al. (2023) · doi:10.1158/0008-5472.c.6512631.v1
Checkpoint Blockade in Hematologic Malignancies
Charalambous, A., & Schwarzbich, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00765-0_178
Utilizing nanomedicines to modulate myeloid-derived suppressor cells: Enhancing cancer immunotherapy
Kumbhar, S., & Bhatia, M. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27731-3.00006-1
Modeling Resistance to Immune Checkpoint Blockade
Quigley, M. M., Meyer, M. J., & Katlinski, K. V. (2022) · Wiley eBooks · doi:10.1002/9781119535331.ch4
Pineda, F. N., & de Jesús, M. (2000) · Investigación Universitaria Multidisciplinaria: Revista de Investigación de la Universidad Simón Bolívar
Effern, M. (2019) · bonndoc (University of Bonn)
Regulation of Tumor Progression and Metastasis by Bone Marrow-Derived Microenvironments
Ramchandani, D., Rayes, T. P. E., Gao, D., Altorki, N. K., Cox, T. R., Erler, J. T., & Mittal, V. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_14
Targeting SYK to alleviate MDSC-driven immunosuppression and augment anti-PD1 efficacy
Zeng, Z., Cao, X., Li, C., He, Y., Guo, H., Cao, X., Gong, T., Sun, J., Hu, Y., Hu, Z., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3230-6
Zemek, R. M. (2019) · UWA Profiles and Research Repository (UWA) · doi:10.26182/k107-nb18
Singh, L., Muise, E. S., Bhattacharya, A., Grein, J., Javaid, S., Stivers, P., Zhang, J., Qu, Y., Joyce-Shaikh, B., Loboda, A. P., et al. (2023) · doi:10.1158/1541-7786.c.6545345.v1
Saas, P., & Perruche, S. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732469343.793544790
Proia, T. A., Singh, M. K., Woessner, R. D., Carnevalli, L. S., Bommakanti, G., Magiera, Ł., Srinivasan, S. S., Grosskurth, S. E., Collins, M. P., Womack, C., et al. (2023) · doi:10.1158/1078-0432.c.6529559
Proia, T. A., Singh, M. K., Woessner, R. D., Carnevalli, L. S., Bommakanti, G., Magiera, Ł., Srinivasan, S. S., Grosskurth, S. E., Collins, M. P., Womack, C., et al. (2023) · doi:10.1158/1078-0432.c.6529559.v1
Li, X., Xu, H., Hong, R., Yang, H., Xu, L., Zheng, G., & Xie, B. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114174
Développement et caractérisation d’une molécule antinéoplasique ciblant l’AMPK et MELK
Cavazza, E. (2021) · theses.fr (ABES) · doi:10.70675/e5e2f0d1zc511z4f8az9fcfz08497d160992
Vétizou, M. (2015) · theses.fr (ABES) · doi:10.70675/6ad24363zc086z46fczb9dazca490b1580b3
Kitano, S., Postow, M. A., Ziegler, C. G. K., Kuk, D., Panageas, K. S., Cortez, C. A., Rasalan, T. S., Adamow, M., Yuan, J. D., Wong, P., et al. (2023) · doi:10.1158/2326-6066.c.6548807
Immunotherapy and multimodality therapy for lung cancer
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4429-7
Lepper, A. (2025) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00036613
Qing, C. (2023) · UCL Discovery (University College London)
Joseph, E. L. M. (2019) · theses.fr (ABES) · doi:10.70675/bba1a27bz36bdz488cza60azf58fa2e47702
Développement d'un agoniste anti-ChemR23 en tant que vecteur de résolution de l'inflammation
Trilleaud, C. (2020) · theses.fr (ABES) · doi:10.70675/40b56131z5a56z4dd4za92bzfd9b187295f2
The toll-like receptor 9 — from immune cells to cancer. Is TLR9 in tumours a cause or a consequence?
Ishizu, T. (2025) · UTUPub (University of Turku)
Immunosénescence, inflammation et immunothérapies
Naigeon, M. (2022) · theses.fr (ABES) · doi:10.70675/f0b0b5e9zc57dz4931z82c0z1510abbc8c2c
Herrmann, H. (2025) · theses.fr (ABES) · doi:10.70675/867ad825z5b04z4910z9659z48e15fd6431a
Personalizing Immunotherapy: Pharmacology and Treatment Selection in Metastatic Cancer
Hurkmans, D. P. (2021) · RePub (Erasmus University Rotterdam)
Tumor Associated Neutrophils in Human Lung Cancer
Eruslanov, E. B. (2016)
Cañas, M. G. (2018) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Cañas, M. G. (2018) · Academica-e (Universidad Pública de Navarra)
担がんマウス生体内に存在する接着性新規免疫細胞の同定と機能解析
椿, 卓., & tsubaki, T. (2018) · Institutional Repositories DataBase (IRDB)
Regulation of myeloid-derived suppressor cells by glutamate
Tachibana, M. (2025) · Folia Pharmacologica Japonica · doi:10.1254/fpj.25009
Statistical Inference Methods to Identify Tumor Microenvironment Heterogeneity
Zhang, H. (2025) · D-Scholarship@Pitt (University of Pittsburgh)
Depleting Immunosuppressive Cells with Tumor Cells to Overcome Acquired Resistance to PD-1 Blockade
Wang, Z. (2022) · WakeSpace Scholarship (Wake Forest University)
Data from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
Owen, D. H., Benner, B. N., Wei, L., Sukrithan, V., Goyal, A., Zhou, Y., Pilcher, C., Suffren, S., Christenson, G., Curtis, N., et al. (2023) · doi:10.1158/1078-0432.c.6533090
Rodrigues, A., Martins, T. M., & Lopes, B. (2025) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/dv66eggjwi
The Gut Microbiome Shapes the Tumor Microenvironment by Tuning Innate Immunity
Fessler, J. L. (2021) · Knowledge@UChicago (University of Chicago) · doi:10.6082/gtnw5-rgy93
Bouaoud, J. (2022) · theses.fr (ABES) · doi:10.70675/8ef3db03z8bb5z4613z9c6azf69f8504431b
Fusobacterium nucleatum mediated crosstalk drives cisplatin resistance in head and neck cancer
Khan, M. D., Ali, M. A., Chaudhry, A., Ahsan, A., & Ahmad, I. (2026) · Oncology · doi:10.1159/ocl/aebag021
HSP90α induces immunosuppressive myeloid cells in melanoma via TLR4 signaling
Arkhypov, I. (2023) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00033947
Chevolet, I. (2015) · Ghent University Academic Bibliography (Ghent University)
Clinical aspects of immunotherapy and targeted therapy of advanced melanoma
Geukes Foppen, M. H. (2018) · Leiden Repository (Leiden University)
Raghani, R. M., Ma, J. A., Zhang, Y., Orbach, S. M., Wang, J., Zeinali, M., Nagrath, S., Kakade, S., Xu, Q., Podojil, J. R., et al. (2022) · doi:10.3389/fonc.2022.1039993.s005
Prioritization of VSV-based OV to overcome ICI-resistant melanomas.
Long, B. R. (2023) · eScholarship@McGill (McGill) · doi:10.82308/2424
TARGETING IMMUNE SUPPRESSION IN GLIOBLASTOMA
Alban, T. J. (2020) · OhioLink ETD Center (Ohio Library and Information Network)
Supporting information 1 of Bv8 Blockade Sensitizes Anti-PD1 Therapy Resistant Tumors
Benguigui, M., Vorontsova, A., Timaner, M., Levin, S., Haj-Shomaly, J., Deo, A., Menachem, R., Manobla, B., Cooper, T. J., Raviv, Z., et al. (2022) · doi:10.3389/fimmu.2022.903591.s001
Sterner, B. (2025) · Refubium (Universitätsbibliothek der Freien Universität Berlin) · doi:10.17169/refubium-47663
Metadata
- Authors
- Meyer, C., Cagnon, L., Costa-Nunes, C. M., Baumgaertner, P., Montandon, N., Leyvraz, L., Michielin, O., Romano, E., & Speiser, D. E.
- Affiliations
- University of Lausanne (CH)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Speiser, Daniel E.
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2013-12-20
- Volume
- 63
- Issue
- 3
- Pages
- 247-257
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11029062
- OpenAlex
- W2080886891
- Cited by
- 560
- References
- 58
- Citations by year
- 2026: 12 · 2025: 37 · 2024: 29 · 2023: 59 · 2022: 64 · 2021: 73 · 2020: 85 · 2019: 49 · 2018: 36 · 2017: 36 · 2016: 33 · 2015: 25 · 2014: 18 · 2013: 1
- FWCI
- 14.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion, other-oa)
- reroDoc Digital Library (submittedVersion)
- IRIS (submittedVersion)
- Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (141879, 135553, 310030)
- Fondation ISREC
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- myeloid-derived suppressor cells, metastatic melanoma, ipilimumab, CTLA-4 blockade, predictive biomarkers, treatment response, monocytic MDSCs, tumor resection, lactate dehydrogenase, immune monitoring
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Cell Count, Female, Humans, Immune Tolerance, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Skin Neoplasms, Treatment Outcome, Lipopolysaccharide Receptors, Myeloid Cells, Biomarkers, Pharmacological, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.